Sickle Cell Disease Association of America, Inc. (SCDAA)
About SCDAA
Sickle Cell Research & Screening
Member Organizations
Media Canter
Annual Convention
Sickle Cell Programs & Eduation
Get Involved
Calendar of Events
Wall of Giving
Join SCDAA
SCDAA
Address
Sickle Cell Disease Association of America, Inc.
3700 Koppers Street
Suite 570
Baltimore, Maryland 21227

Office   410.528.1555
Fax   410.528.1495
Toll Free   800.421.8453


Monday - Friday:
9:00am - 5:00pm (EST)

scdaa@sicklecelldisease.org
  • Sickle Cell Conditions
News

White House Response to SCD Petition!

Last fall, SCDAA and the sickle cell disease (SCD) community issued a public petition to the White House, requesting reauthorization of the Sickle Cell Treatment Act, declaration of SCD as a national priority and funding for SCD programs in the President's budget. Recently the petition's success came into fruition...

White House Response to SCD Petition!
Sickle Cell

The SCDAA has been awarded the Health Resources and Services Administration (HRSA), Sickle Cell Disease Newborn Screening Program Grant!

SCDAA has been designated to serve as the National Backbone Organization for the HRSA Sickle Cell Disease Newborn Screening Program. As the national backbone organization SCDAA will work with community-based organizations across the country to implement a strengthened approach to care, collective impact and...

The SCDAA has been awarded the Health Resources and Services Administration (HRSA), Sickle Cell Disease Newborn Screening Program Grant!
Sickle Cell

2015 Convention Planning is Under Way!

Our 43rd Annual Convention will take place September 23 - 26, 2015. Stay informed on all things convention related! Learn about this year's host hotel, events, announcements and abstract deadlines. Convention will be here before we know it!

2015 Convention Planning is Under Way!
Sickle Cell


Chief Medical Officer News

Pfizer Announces Enrollment Of First Patient In Phase 3 Trial

Pfizer Inc. announced that the first patient has been enrolled in the RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) study – a Phase 3 clinical trial assessing the efficacy and safety of rivipansel for the treatment of vaso-occlusive crisis in hospitalized individuals with sickle cell...

Pfizer Announces Enrollment Of First Patient In Phase 3 Trial
Sickle Cell


Advocacy Update


Thank You to All Who Participated in the 2015 National Sickle Cell Advocacy Day!
Advocacy Day was once again a huge success!
Click Here to Learn More about the Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2015
Featured Event
Featured Event
Featured Event
SCDAA Corporate Sponsor